Screener
Ligand Pharmaceuticals LGND EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Ligand Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's EBITDA margin?
- Ligand Pharmaceuticals (LGND) reported EBITDA margin of 43.9% in Q2 2026.
- How has Ligand Pharmaceuticals's EBITDA margin changed year-over-year?
- Ligand Pharmaceuticals's EBITDA margin increased by 12638.2% year-over-year, from 0.3% to 43.9%.
- What is the long-term trend for Ligand Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's EBITDA margin has grown at a -3.8% compound annual growth rate (CAGR), from 33.9% to 27.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Ligand Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude